(R)-VX-984

• CAT Number: I018271
• CAS Number: 2448475-19-0
• Molecular Formula: C23H21D2N7O
• Molecular Weight: 415.49
• Purity: ≥95%
• Synonyms: 8-[(2R)-1-[[6-(4,6-dideuterio-2-methylpyrimidin-5-yl)pyrimidin-4-yl]amino]propan-2-yl]-N-methylquinoline-4-carboxamide
• InChI: InChI=1S/C23H23N7O/c1-14(17-5-4-6-18-19(23(31)24-3)7-8-25-22(17)18)10-28-21-9-20(29-13-30-21)16-11-26-15(2)27-12-16/h4-9,11-14H,10H2,1-3H3,(H,24,31)(H,28,29,30)/t14-/m0/s1/i11D,12D
• InChIKey: PEACIOGDEQRHFA-WXFXTCFHSA-N
• SMILES: [2H]C1=C(C(=NC(=N1)C)[2H])C2=CC(=NC=N2)NC[C@H](C)C3=CC=CC4=C(C=CN=C43)C(=O)NC

(R)-VX-984（Cat No.:I018271）is a selective small-molecule inhibitor targeting DNA-dependent protein kinase (DNA-PK), a critical enzyme in the non-homologous end joining (NHEJ) pathway of DNA double-strand break repair. By blocking DNA-PK activity, (R)-VX-984 enhances the sensitivity of cancer cells to ionizing radiation and chemotherapeutic agents, offering promise as a radiosensitizer in oncology. Its stereospecific (R)-enantiomer provides improved potency and selectivity for DNA-PK. This compound is widely explored in cancer disease research, particularly for overcoming resistance to conventional therapies and advancing strategies in DNA damage response modulation.